Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245722 · ClinicalTrials.gov registry record · Phase 1
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT04245722: Clinical Trial Phase 1 study, sponsored by Fate Therapeutics.
NCT04245722 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04245722, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG FT596
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2020-03-19 |
| Est. Completion | 2023-09-27 |
| Phase | Phase 1 |
Why NCT04245722 stopped before completion
NCT04245722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT04245722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04245722 about?
NCT04245722 is a clinical study titled "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies". This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enr...
What is the current status of trial NCT04245722?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2020-03-19. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT04245722?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), FT596 (DRUG).
Who is sponsoring clinical trial NCT04245722?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04245722's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI